Private equity firm Taconic has completed the sale of Iron Horse Labs, a biotech company specializing in advanced cell and gene therapies, for $73 million. The acquisition highlights the growing investor interest in biotech startups focused on innovative medical treatments. The deal underscores the financial potential of early-stage biotechnology firms as they advance toward clinical development. Industry observers will watch to see how the new ownership may shape the company’s future research and commercialization efforts.
